Clinical Trial

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-09.
Trial Details
NCT Number NCT06932471
Lead Sponsor Wuhan Createrna Science and Technology Co., Ltd
Conditions Paroxysmal Nocturnal Hemoglobinuria
Enrollment 20 participants
Start Date 2024-08-30
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-09